Resumo

DAMIAN-BLANCO, Paola et al. Use of monoclonal antibodies in cancer immunotherapy: types and mechanisms of action. Bol. Med. Hosp. Infant. Mex. [online]. 2023, vol.80, n.3, pp.153-164.  Epub 11-Set-2023. ISSN 1665-1146.  https://doi.org/10.24875/bmhim.23000123.

Immunotherapy is one of the most innovative treatments in the current field of oncology and consists of stimulating the immune system to eliminate tumoral cells. Monoclonal antibodies (mAbs) are glycoproteins secreted by B-cells capable of recognizing and neutralizing foreign organisms or antigens. Structurally, they are composed of two heavy and two light chains. The generation of therapeutic mAbs is one of the most developed and fastest-growing areas of the biotechnological and pharmaceutical industries and is an important adjunct to cancer therapy. Several antibodies have been approved for human administration and can be mouse-derived, chimeric, humanized, or fully human. mAbs main mechanism of action includes the lysis of the tumoral cells through inducing apoptosis, phagocytosis, complement activation, or signaling inhibition.

Palavras-chave : Cancer; Immunotherapy; Monoclonal antibodies; Mechanism of action.